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distinguish one individual from another, even across mul-
tiple health plans. In developing this longitudinal dataset,
a series of administrative and technical issues were
addressed—the evaluation of claims data as proxies for
evaluating clinical measures, methods for standardizing
data from multiple sources, the identiﬁcation of providers
from multiple data sources and with multiple identiﬁers,
building time-horizons and data integrity checks that
work across the disparate data sources. RESULTS: Strong
Square, LLC has datasets that contain masked patient-
speciﬁc data and unique provider identiﬁcation that
allows for tracking a patient’s utilization of antibiotic pre-
scriptions over time and over multiple health plans.
CONCLUSIONS: This project provided physicians with
a single, uniﬁed reporting mechanism that measures each
physician’s antibiotic prescribing patterns. Because of the
data methods, tools and processes developed for this ini-
tiative, we are reporting a complete “picture” of physi-
cian antibiotic prescribing patterns across all major health
care payors in the State of Washington over time without
revealing patient-identity.
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OBJECTIVES: Inappropriate use of antibiotics is now a
well documented international health issue with implica-
tions for cost of care and antibiotic resistance. The objec-
tive of this study is to estimate the probability of receiving
an antibiotic for an “inappropriate” diagnosis. Prescrib-
ing behavior, in general, has been the subject of research
in many countries, but predictors of antibiotic prescrib-
ing have received little attention. METHODS: South Car-
olina Medicaid paid claims for 1996 to 2000 are used to
estimate probabilities of receiving an antibiotic prescrip-
tion for an upper respiratory infection (URI). Patient 
variables include demographics (age, race, gender,
urban/rural location), URI history, ambulatory-service
history, and hospital-use history, and URI diagnosis. Pre-
scriber variables include practice load, URI patient mix,
and practice specialty), and urban/rural location of prac-
tice. Probit analysis is used to estimate the probability of
receiving an antibiotic prescription for a viral URI diag-
nosis. Year of service is included with the above variables
to estimate a full-model. RESULTS: Probability estimates
indicate that the most likely recipient of an antibiotic for
a viral URI was female (0.270), non-white (0.269), and
age 5 to 18 year old (0.326). Among prescribers the prob-
ability was highest for generalists (0.354), and pediatri-
cians had a probability of 0.226. Overall, from 1996 to
2000, the rate of antibiotic prescribing for viral URIs
decreased from 39% to 27%. Shifts in antibiotic use pat-
terns also were observed with amoxicillin being the most
frequently used drug in 1996 at 42%. Amoxicillin main-
tained its dominant position over the study period but
newer antibiotics increased their share of total utilization.
CONCLUSIONS: There was a general decline in antibi-
otic use from 1996 to 2000, but the rate of antibiotic 
prescribing for viral URIs remains high. The methods
employed to track antibiotic use offer a relatively inex-
pensive approach to identifying and tracking potentially
inappropriate prescribing.
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The possibility of performing complete simulations of
clinical trials, based on pharmacological action models,
has been considered since the advent of the computer era,
as a tool to optimise their practical realisation. Thanks to
the advances in computation technology and in discrete
event simulation tools, today it is possible to perform
realistic, large-scale clinical trial simulations in a regular
basis using suitable simulation tools. OBJECTIVES: We
illustrate the process of use the realistic simulator
LeanSim, previously for the concrete case of pilot clinical
trials devoted to testing efﬁcacy of the antiretroviral
didanosine in a group of 50 patients with virologic failure
presenting different mutations in the gen of HIV reverse
transcriptase. It can origin resistance to transcriptase
inhibitors and it can affects the efﬁcacy of treatment
designed to reduce the viral load in AIDS patients.
METHODS: LeamSim is basically a discrete simulation
tool developed in C/C++ that can be applied in any ambit,
but accepts personalised elements construction, in order
to adapt the simulation model to the reality that want to
be simulated (this is the lean simulation metaphor). Other
important LeanSim aspect is the way in with the model
is constructed, this is, via the process deﬁnition, which 
is closer to the clinical trials experiment deﬁnition.
RESULTS: LeanSim allow the population variability sim-
ulation (inter/intra patients) and its low cost let general
use extend during optimisation previously the clinical
trial starts. CONCLUSIONS: A simulation model based
in Linear Mixed Models was estimated and during the
simulation various scenarios were simulated to optimise
sample size, effect of missing values, number of centres
recruiting patients and the variability inter/intra patients
and the previous results indicate the advantages of use
this new tool. 
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